After Fresenius (FMS) agreed to manage Humana's Medicare Advantage members with end stage renal disease, Bernstein analyst Lisa Bedell Clive says that the deal is "very positive" for Fresenius' care coordination business. She notes that Humana is the second largest Medicare Advantage provider in the U.S., and she estimates that the deal will cover 3,000 patients, versus the 1,000 that Fresenius covers for Aetna (AET) and the 750-1,000 it covers for Cigna (CI). The analyst estimates that the deal will raise Fresensius' 2018 revenue by $210M and its 2018 EBIT by $30M. She expects the unit's profitability to reach a positive turning point in 2018, and she keeps an Outperform rating on the shares.